Post-marketing surveillance business using nationwide locations and AR personnel
First written in FY2016. 4 of 8 entries say "Restated". Latest entry: 2026-05-14.
0 other companies' latest entry also says "Other".
- 2026-05-14OtherEarningsSuggests it is closing out
「ファルフィールド Co., Ltd. has been excluded from the scope of consolidation because it transferred its business during the consolidated fiscal year, resolved to dissolve in March 2026 and no longer has a material impact on the consolidated financial statements.」
The business transfer and dissolution resolution of ファルフィールド were disclosed, indicating the conclusion of the previous structure of the PMS business. - FY2021-Q3AdvancedAnnual report
「As part of this initiative, 株式会社ファルフィールド (Koto-ku, Tokyo) was established in October 2020 with the aim of developing the PMS business into a new revenue-generating business, and in January 2021 the business conducted by 3 wholesale companies for prescription drugs and other products was consolidated under the new company. Going forward, we will establish an even higher-quality and more agile operating structure and expand the scope of services to include a broad range of contract work for clinical research and clinical trials, in addition to this business.」
For the PMS business, operations that had been spread across 3 companies were effectively consolidated under ファルフィールド. This reflects the development of the operating structure since January 2021 and the expansion of the scope of contracted clinical research and clinical trial services. - FY2021-Q2AdvancedAnnual report
「In October of the same year, with the aim of developing the PMS business into a new source of revenue, the Group established Farfield Corporation (Koto Ward, Tokyo). The PMS operations currently conducted by 3 wholesale companies for prescription pharmaceuticals and other products will be consolidated into the new company. From January 2021, the Group will establish a higher-quality, more agile structure and will also broadly undertake clinical research and clinical trials in addition to the existing business.」
A new company was established to consolidate the PMS operations previously conducted by 3 companies into Farfield, with plans to establish a more agile structure from January 2021 and expand the scope of contracted work to clinical research and clinical trials. - FY2018RestatedAnnual report
「In existing businesses, the Group aims to improve productivity centered on ALCs, while in new businesses it seeks to expand its earnings base through initiatives including AR promotion and post-marketing surveillance (PMS).」
The Group continues its AR promotion and PMS initiatives, using nationwide infrastructure and AR personnel to expand its earnings base through new businesses. - FY2017-Q3RestatedAnnual report
「The Group also operates a business conducting part of the post-marketing surveillance (PMS) process for pharmaceutical companies on a contract basis, using personnel resources including business locations nationwide and ARs.」
The Group continues its contracted PMS business using nationwide locations and personnel including ARs. - FY2017-Q2RestatedAnnual report
「The Group also operates a business conducting part of the post-marketing surveillance (PMS) process for pharmaceutical companies on a contract basis, using personnel resources including business locations nationwide and ARs.」
The Group continues its contracted PMS business using nationwide locations and personnel including ARs. - FY2017-Q1RestatedAnnual report
「The Group also operates a business conducting post-marketing surveillance (PMS) for pharmaceutical companies on a contract basis, using personnel resources including business locations nationwide and ARs.」
The Group continues its contracted PMS business using nationwide locations and personnel including ARs. - FY2016First statedAnnual report
「The Group operates a business conducting post-marketing surveillance (PMS) for pharmaceutical companies on a contract basis, using personnel resources including business locations nationwide and ARs.」
The business is expanding into services for pharmaceutical companies outside wholesale by using its existing nationwide locations and specialized personnel.